Tcelltech Biotech

Tcelltech is a clinical-stage biotechnology company specializing in the development of next-generation T-cell immunotherapies for the treatment of solid tumors. The company utilizes its proprietary TRUST (T-cell Receptor Universal Survival Technology) platform to enhance the persistence and efficacy of engineered T-cells within the immunosuppressive tumor microenvironment. Its pipeline includes both CAR-T and TCR-T programs targeting high-value antigens such as GPC3, HPV16 E7, and NY-ESO-1. Tcelltech operates R&D and manufacturing facilities in both China and the United States to support its global clinical development strategy. The company aims to provide curative treatment options for patients with refractory or metastatic cancers through its "armored" cell therapy approach.